Nurses Trial Table


How to contact our nurees/trials team:
 
 

Trial/Study

Lead Nurse/Contact

Ext

Bleep

Acute Pancreatitis Biobank

The collection and storage of samples of urine, serum, plasma, RNA and white cell preparations from patients with Acute Pancreatitis.

Sister Lorna Fleming

4636

5000

Chronic Pancreatitis Biobank

The collection and storage samples of bloods from patients with Chronic Pancreatitis.

Simon Winn

4487

 

EUROPAC
Secretin stimulated endoscopic collection of duodenal aspirate for the analysis of molecular markers for the early detection of pancreatic cancer:
To validate a technique of pancreatic juice collection, which will prevent exposure to the risk of ERCP pancreatitis by avoiding pancreatic duct cannulation.

c/o Andrea Sheel, Clinical Research Fellow

4168

ChroPac
Duodenum-preserving head resection versus pancreatico-duodenectomy for chronic pancreatitis of the head – A randomized controlled multicentre trial (ChroPac).
To investigate differences in Quality of Life (QoL) during 24 months after surgery of duodenum-preserving pancreatic head resection (DPPHR) versus pancreatico-duodenctomy (PD).     

Sister Lorna Fleming

4636

5000

ESPAC-3 (V2)
European Study Group for Pancreatic Cancer (ESPAC) Trial 3 (v2). Adjuvant Chemotherapies in Resectable Pancreatic Cancer.

Pancreatic cancer is one of the major causes of cancer death in Central and Northern European countries as well as in North America, Australasia and Japan 1. Initial treatment involves surgical resection Despite recent improvements in resection rates for localised pancreatic cancer, long-term survival following surgery alone remains poor with a median of 11-15 months, 2-year survival of 20-40% and 5-year survival of around 10% 2, 3. ESPAC-3 was formulated as a result of the ESPAC-1 study.

Sister Pembe Yesildag

3898

4467

ESPAC4
European Study Group For Pancreatic Cancer (ESPAC) -Trial 4. Combination versus single agent adjuvant chemotherapy in resectable pancreatic cancer.

Long term survival following resection for pancreatic cancer still needs to be improved. Adjuvant 5-FU/FA demonstrates significant improvement in overall survival following surgery, adjuvant gemcitabine demonstrates a survival advantage following surgical resection for pancreatic cancer. Gemcitabine plus capecitabine improves survival in patients with advanced pancreatic cancer compared with single agent gemcitabine.

Sister Pembe Yesildag

3898

4467

ESPACT+
The ESPAC-1 trial has shown that pancreatic ductal adenocarcinoma is responsive to adjuvant chemotherapy (5FU). The ESPAC-3 trial is now comparing adjuvant 5-FU and gemcitabine. ESPAC-TPlus is designed to allow both prospective and retrospective sample collection and analysis.

Sister Pembe Yesildag

3898

4467

EUROPAC 2

c/o Andrea Sheel, Clinical Research Fellow

4168

PANasta 

Pilot for phase III Cattell Warren verses Blumgart techniques of pancreatico-jejunostomy following pancreato-duodenectomy - a double-blinded multi-centred trial.

Please see LCTU website

PanGen-EU
The objectives of the PanGen –EU study are to:

  1. assess the environmental and genetic risk factors responsible for sporadic pancreatic cancer
  2. to identify families with an aggregation of relatives suffering from pancreatic cancer

to act as a repository of biological samples and clinical information for the MOLDIAG EU Consortium.

c/o Simon Winn

4168